MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US

SAN DIEGO--(BUSINESS WIRE)--MedImpact Holdings Inc. today announced that it will have access to an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than the reference Stelara® (ustekinumab). The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., will be available for direct purchase from MedImpact’s preferred partner, Birdi, Inc., by any licensed specialty pharmacy. “Today, a drug’s cost rises at each step in the supply chain,” said Arpit Patel,